Grifols, ES0171996087

Grifols stock reports 28.70 percent profit growth in H1

Published on 09/29/2026 at 13:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached EUR 3.574 billion on July 28, 2026, while adjusted EBITDA was EUR 854 million. Grifols stock also carries a U.S. Biopharma IPO option.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament — Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) was trading at EUR 9.75 at Lang & Schwarz on September 29, 2026, at 1:15 p.m. CEST. According to Grifols in its investor release dated July 28, 2026, first-half profit rose 28.70 percent to EUR 227 million, giving the stock a concrete earnings anchor.

Profit growth leads the recovery

First-half revenue reached EUR 3.574 billion, with growth of 2.60 percent at constant currency. The comparison is important because profit increased much faster than revenue, pointing to operating improvement rather than a volume-led expansion alone.

The company also reported EUR 854 million in adjusted EBITDA for the first half, up 2.40 percent at constant currency, with an adjusted EBITDA margin of 23.90 percent. As Yahoo Finance reported in the July 28, 2026 earnings-call transcript, free cash flow before mergers and acquisitions reached EUR 91 million, an EUR 103 million year-over-year improvement.

Biopharma supplies the growth

Biopharma revenue grew 5.40 percent at constant currency in the first half, outpacing the group and making immunoglobulins the main operating driver. That mix matters for investors because the higher-growth business is also the company division most closely tied to plasma collection efficiency and product demand.

Management also said the board had started evaluating a potential initial public offering for the U.S. Biopharma business. The transcript described the process as subject to legal, regulatory and internal approvals, so the option is strategic rather than a completed transaction.

Renewable power adds a measurable step

A separate company release dated September 16, 2026, reported by MarketScreener, said Grifols will receive 40 GWh of renewable electricity annually for 10 years. The agreement is expected to cover 66 percent of the company's electricity demand in Spain, adding a defined cost and sustainability element to the operating picture.

EUR 9.75 in afternoon trading

Grifols was trading at EUR 9.75 at Lang & Schwarz on September 29, 2026, at 1:15 p.m. CEST. Its primary listing is BME in Spain, where the shares trade in euros under GRF; the Lang & Schwarz quote is the reference price for investors in Germany.